Daily Archives: 17, June 2015

Thailand’s CAT Telecom Selects Elitecore’s BSS Platform to Enable MVNE Strategy

MUMBAI, India & BANGKOK, Thailand, 17-6-2015 — /EuropaWire/ — Elitecore Technologies, a leading global provider of Next-generation BSS and Packet Core solution announces that, Thailand based CAT Telecom, a leading Tier 1 Telecom Operator and Suvitech a Thailand based IT … Read the full press release

Novartis confirms benefits of first-line Tasigna treatment seen in earlier trials in newly-diagnosed patients with chronic myeloid leukemia (CML)

Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of Tasigna in newly-diagnosed CML patients seen in the pivotal ENESTnd study … Read the full press release

20th EHA Congress in Vienna: Novartis data shows increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myeloma

Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an incurable cancer of the plasma cells, a type of white blood cell … Read the full press release

Novartis: Arzerra significantly improves median progression-free survival when added to fludarabine + cyclophosphamide after initial treatment stopped working in patients with relapsed chronic lymphocytic leukemia

Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus existing CLL treatments also had a higher overall response rate (84% vs 68%) compared to … Read the full press release

Novartis: Xolair helps patients with Chronic Spontaneous Urticaria (CSU) achieve significant improvements in quality of life measures

New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2] Additional data at WCD show the consistent negative health impact and economic burden of CSU, … Read the full press release

Novartis: US FDA approved Promacta for the treatment of children six years and older with chronic immune thrombocytopenia (ITP)

Promacta® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low platelet count[1], ITP can affect up to 5 in 100,000 children each year[2] and … Read the full press release